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INTEGRATIVE NEUROSCIENCE
and discussing ethical issues. This contribution will give an  overview 
of these discussions, based on a review of the relevant medical and 
ethical literature.
Ethical issuEs in trEatmEnt of nEurological 
disordErs
An ethical assessment of DBS treatment can depart from – and be 
structured by – the four basic principles of medical ethics: non-
maleficence, beneficence, justice and respect for autonomy, and the 
additional principles of subsidiarity and proportionality (Table 1).
Balancing BEnEficEncE and non-malEficEncE
The first important ethical question is whether DBS is beneficial and 
does not harm the patient. In other words: are the expected risks 
and side-effects proportional to the expected benefits? This must be 
assessed both at a group-level and at the level of individual patients. 
At the group-level, this means that the available evidence regarding 
effectiveness, risks, and side effects of DBS for various conditions, 
in various target areas, and for various patient-populations must 
be assessed.
For disorders like PD, dystonia, and essential tremor DBS has 
been proven to be effective.
The risks and complications associated with DBS surgery 
include hemorrhage (1.3–4%), infection (2.8–6.1%), lead migra-
tion, misplacement or breakage (5.1%), and even death (0.4%; 
Clausen, 2010). Side effects depend partly on the stimulation target 
and include effects on cognition, behavior and psyche, including 
speech disturbances (10.8–33%), memory impairment (1.1–20%), 
aggression (2%), (hypo)mania (2–28%), hypersexuality (0.8%), 
depression (1.5–25%), and increased suicide risk (Clausen, 2010). 
introduction
Deep brain stimulation (DBS) is currently used to treat  neurological 
disorders like Parkinson’s disease (PD), essential tremor and dys-
tonia, and is explored as an experimental treatment for psychiatric 
disorders like major depression (MD) and obsessive compulsive 
disorder (OCD).
Since DBS involves brain surgery and modulation of brain-
states, it may invoke reminiscences of unethical neurosurgical 
practices from the past. For instance, it may remind one of the 
lobotomies performed by Moniz and Freeman or of the Tulane 
electrical stimulation program by Heath. Images from works of 
popular fiction, such as One Flew Over the Cuckoo’s Nest or The 
Manchurian Candidate, in which interventions in the brain are 
used to manipulate or otherwise abuse people, may also come to 
mind. Such images may influence the public perception of DBS 
and related ethical issues. There are, however, clear differences 
between past forms of neurosurgery and current DBS, which make 
the comparison go awry. Most importantly, operation techniques 
such as MRI-guided stereotactic surgery have improved and the 
intervention is therefore much safer. Moreover, the effects of 
DBS are mostly reversible – the stimulation can be turned off 
if it is not effective or causes too many adverse effects. Unlike 
some of the controversial neurosurgical interventions in the past, 
DBS is performed only in otherwise treatment-resistant patients, 
and only with informed consent from the patient (Synofzik and 
Schlaepfer, 2008).
Still, DBS raises some important ethical issues, both in the 
context of treatment and in that of research. These issues have 
been discussed in the medical as well as bioethical community, and 
researchers from both fields have often collaborated in  identifying 
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This emphasizes the need for good pre-operation  counseling and 
the provision of clear and honest information in the informed 
consent process. Moreover, these findings point to the unsettling 
effects of successful treatment. Paradoxically, regained function-
ing may upset established social and relational patterns. Many 
patients have difficulties with psycho-social adjustment after 
surgery, especially with regard to their marital relationships, 
self-perception, and work. After surgery, a period of adaptation 
is necessary for both patients and their families. This requires 
professional psycho-social preparation and follow-up support 
(Schüpbach et al., 2006).
changEs in pErsonal idEntity – a spEcial kind of sidE EffEct?
A special and frequently mentioned concern regarding the side 
effects of DBS is that changes in behavior, mood, or cognition 
caused by DBS might result in changes in “personal identity.” The 
ethical discussion on this point is complicated by the lack of clear 
and undisputed definitions of central concepts such as personal-
ity, self, identity, and authenticity (Merkel et al., 2007). A useful 
distinction can be made between numerical identity and narrative 
identity (Schermer, 2009a; Schechtman, 2010). The first refers to 
continuity of the same person over time, defined by bodily criteria 
(like DNA), or psychological criteria such as (autobiographical) 
memory or a set of core-characteristics. A change in numerical 
identity would mean that someone literally became someone else. 
If DBS would cause changes in mood, cognition, or behavior that 
would affect numerical identity (e.g., by completely wiping out or 
changing biographical memory), they would indeed be problematic 
since they would put people out of existence and create new people. 
This is not the case, however.
The relevant notion of personal identity is therefore narrative 
identity, which involves the person’s self-conception, his biography, 
values, and roles as well as his psychological characteristics and 
style. It is the answer to the question “who am I?” A person’s person-
ality, defined by the DSM as “the enduring patterns of perceiving, 
relating to, and thinking about the environment and oneself that 
are exhibited in a wide range of social and personal contexts,” is 
thus part of his narrative identity. Mood, cognitions and behavior 
are also part of one’s personal narrative.
Changes in narrative personal identity are not necessarily 
ethically problematic in themselves – that is, apart from pos-
sible harmful consequences for others. People always change in 
many respects throughout their lives; personal identities are not 
static but develop over time. Disorders such as PD or dystonia 
can have a profound impact on the development of a person’s 
identity, as can their (successful) treatment. Some of the changes 
that DBS can bring about in personality, cognition, behavior, or 
mood may actually be sought by the patient and be the goal of 
treatment, for example mood improvement in depression, or 
tic-reduction in Tourette’s syndrome. Other changes may not be 
intended but can still be welcomed by the patient, for example 
an elevated mood or increased libido. The same changes can, 
however, be evaluated differently by different patients. The rel-
evant ethical point is therefore whether or not the patient himself 
perceives the changes in his personality, mood, behavior, or cog-
nition brought about by DBS as disruptive of his personal nar-
rative identity (Schermer, 2009a; Synofzik and Schlaepfer, 2008). 
The principle of subsidiarity implies that DBS should only be used 
when other less risky or burdensome treatment options have been 
exhausted.
patiEnt sElEction
In order to secure a favorable risk–benefit ratio for individual 
patients, careful patient selection is necessary. Patients need to 
stand a good chance to benefit from the procedure, have severe 
functional impairments and be refractory to other, less invasive 
or less burdensome, treatments. Also, candidates should be physi-
cally, cognitively, and emotionally capable of tolerating surgery 
and participating in postoperative care (Bell et al., 2009). This is 
best assessed in a multidisciplinary team (Kubu and Ford, 2007). 
Progress in DBS research may provide new insights that justify an 
expansion of indications for DBS. For example, it may prove to 
be beneficial for PD patients to start DBS treatment earlier in the 
disease process, because this may have a neuroprotective effect, or 
because it may prevent psycho-social problems related to advanced 
PD. In essential tremor, on the other hand, earlier intervention may 
not be beneficial because tolerance may develop.
good carE
With regard to the side effects of DBS it is increasingly recognized 
that these include not only physical or psychiatric symptoms. The 
psycho-social impact of the DBS treatment and the effects on 
overall quality of life should be included as well. Several studies 
have found that sometimes “the doctor is happy, the patient less 
so” (Agid et al., 2006), and DBS has been described as “a unique 
form of biographical disruption” (Gisquet, 2008). It was found 
that quality of life on aspects such as emotional well-being, social 
support, and interpersonal relationships may actually decrease 
after surgery, even when physical symptoms improve. These 
findings may be partly due to unrealistic expectations of patient. 
Table 1 | Deep brain stimulation and the basic principles of medical 
ethics.
Ethical principle Issues pertinent to DBS 
treatment
Non-maleficence, “first, do no 
harm”
• Risks
• Side effects (physical and mental)
• Change in personal identity?
• Effects on developing brain?
Beneficence, “do well” • Effectiveness
• Need for psycho-social care
Proportionality and subsidiarity, 
“risks and benefits in proportion,” 
“choose least burdensome 
alternative”
• Patient selection:
 Risks proportional to benefits?
 Refractory to other treatments?
Justice, “treat like cases alike” • Rationing and prioritizing 
Respect for autonomy, “respect 
patients’ well-informed choices”
• Informed consent
•  Desperation and unrealistic 
expectations
• Competence to consent
• Use in minors
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enabled to make his own autonomous decisions considering the 
further course of action. Fortunately, dramatic dilemma-situation 
as in the case report by Leentjens et al. (2004) – where a PD patient 
had to choose between being either completely bed-ridden but 
competent, or physically improved but manic – seem to be rare.
spEcial groups: childrEn
Deep brain stimulation treatment in children or adolescents, e.g., 
for dystonias or tic disorders, warrants extra ethical attention. First, 
because children are incompetent to decide for themselves about 
risks and benefits and are therefore more vulnerable to abuse. While 
this is no reason to exclude them from beneficial treatment – par-
ents can act as representatives and make decisions in the best inter-
est of their child – it necessitates an extra careful assessment of the 
risk–benefit ratio. Second, research on DBS in children is scarce. 
Only 35 children have been treated for dystonia and so there is 
little evidence regarding benefits and risks in children especially 
regarding long term effects on the developing brain (Lipsman 
et al., 2010). DBS treatment for neurological disorders in children 
should therefore be regarded as experimental and should only be 
performed by highly specialized teams and within well-designed 
and independently reviewed research protocols.
A special case that generates significant controversy concerns 
DBS treatment for treatment-refractory Tourette’s syndrome. 
Because the majority of Tourette’s patients have meaningful clini-
cal improvement in adolescence or early adulthood, it is very ques-
tionable whether the immediate benefits that DBS may give these 
children in the short term, will eventually outweigh the risks in 
the longer run. Moreover, evidence of effectiveness of DBS is very 
limited, even in adult Tourette’s patients (Sassi et al., 2010). A con-
sensus seems to be developing that only in extreme cases where tics 
cause spinal cord injury or myelopathy DBS may be considered as 
last-resort treatment in children (Lipsman et al., 2010).
Ethical issuEs in invEstigational trEatmEnt for 
psychiatric disordErs
Many new indications for DBS are currently investigated, among 
which many psychiatric disorders such as MD, OCD, and addiction. 
For clinical research involving human subjects the fundamental 
ethical challenge is to promote high-quality scientific research in the 
interest of (future) patients, while at the same time safeguarding the 
rights and interests of vulnerable research subjects. In the United 
States and Europe, national and international regulations apply to 
scientific research with human subjects and Institutional Review 
Boards (IRBs) or local ethics committees oversee their observance. 
With regard to DBS research in psychiatric disorders a number 
of ethical requirements have been specified and guidelines have 
been proposed by experts from the field (Nuttin et al., 2002; Kuhn 
et al., 2009; Rabins et al., 2009). The ethical principles underly-
ing these guidelines are respect for autonomy and protection of 
research subjects, benefit for future patients, quality of research, 
and  transparency (Table 2).
rEsEarch Ethics guidElinEs
Important and generally agreed upon recommendations are 
that research with DBS for psychiatric disorders should only be 
performed in expert centers, with experienced multidisciplinary 
Moreover, the acute, rapid changes that DBS can bring about, can 
disrupt the normal, “narrative flow of life” and it may take time 
and effort of the patient to pick up and continue his life story 
(Schechtman, 2010). This may well account for the adjustment 
problems discussed above. Finally, if changes in personality and 
behavior negatively affect others, this may raise the problem of 
responsibility (see Schermer, 2009b).
JusticE
Little has been written on the issue of justice with regard to DBS 
treatment. DBS is an expensive form of treatment, although it has 
been argued that DBS may turn out to be cost effective in the longer 
run as compared to alternative treatment options (Bell et al., 2009). 
In the face of scarcity of resources, it may be necessary to prioritize 
between (groups of) patients. From a perspective of justice, ideally, 
priority should be given to those who are most seriously impaired 
and who will benefit the most from the intervention. Priority setting 
becomes more difficult when “chance to benefit” and “seriousness of 
impairment” do not go together. Anyway, one should be careful not to 
exclude patients who might benefit from the procedure on grounds 
not related to expected benefit, for example because of their age.
autonomy and consEnt
Patients undergoing DBS must give their voluntary and fully 
informed consent to this procedure, just like for any other medi-
cal intervention. In practice this may be problematic for a number 
of reasons. First, some patients may be desperate because of their 
hopeless situation, suffering as they are from a serious, progres-
sive, and treatment-refractory disease. They may feel they have no 
other option but to consent to the proposed treatment. However, 
this is not a unique situation for DBS and the fact that there are 
no other treatment options left does not imply that consent is not 
voluntary. Second, patients’ hopes and expectations of DBS may 
have been raised to unrealistic levels by enthusiastic media reports 
(Bell et al., 2010). Balanced and realistic information is therefore 
needed, not only regarding risks and side effects of the procedure 
but also regarding the expected benefits and the limitations of this 
treatment. It must be clear to patients, for example, that DBS will 
not cure their PD and will not stop its progression.
Another important consideration is the patient’s competence 
to consent to treatment. Competence can be challenged by the 
primary neurological disorder, or by co-morbidity like cognitive 
impairments or depression. It can however also be affected by 
DBS itself (Glannon, 2009).
Deep brain stimulation can, for example, induce a (hypo)manic 
state in patients and there are case reports of such patients who 
subsequently refuse adaptation of the stimulator settings because 
they are not aware of their disturbed mental state. These patients 
may harm themselves or others, for example by excessive gam-
bling or reckless driving. Here, assessment of competence to decide 
is crucial to determine whether or not the treatment team may 
change the settings or discontinue treatment without the patient’s 
consent. If an incompetent patient inflicts severe harm on himself 
or others, it is ethically justified to intervene, under conditions of 
proportionality and subsidiarity. Because the effects of DBS are 
reversible, adjustment of settings or discontinuation of stimulation 
can restore the patient’s competence. In this way, the patient can be 
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teams. An IRB should review the research protocol and monitor 
the research-process. The research goals should include finding the 
appropriate anatomic sites and stimulation parameter, and compar-
ing safety and efficacy of DBS with established treatments. Patient 
selection should be conducted carefully, and only severely afflicted 
and otherwise treatment-refractory patient should be included. 
Informed consent should be obtained, making sure the patient is 
competent and has realistic expectations and is not drive by sheer 
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desperation and unrealistic hopes. According to Rabins et al. (2009) 
only adults and no children should be included. In general, experi-
mental treatment should only be performed within the context 
of an established, duly constituted and independently reviewed 
research protocol. This will protect research subjects, as well as 
ensure that the experimental treatment will add to our scientific 
understanding of DBS and thus be potentially beneficial to future 
patients. Because of the importance of creating a sound evidence 
base and in order to prevent publication bias the creation of an 
independent registry has been proposed, both for trials and single-
case studies (Rabins et al., 2009; Schlaepfer and Fins, 2010).
Long term follow up by a multidisciplinary team is ethi-
cally required both to ensure the well-being of the research 
subjects as for the benefit of future patients. This follow up 
should include safety and efficacy but also quality of life and 
psycho-social effects; follow up should also take into account 
information provided by a person close to the patient (Kuhn 
et al., 2009).
conflicts of intErEst statEmEnt
One ethical issue that has great salience in DBS research concerns 
the role of the industry. As Fins and Schiff (2010: 125) state: “clinical 
research in DBS presents a unique nexus of science and commerce 
in which market forces influence the contours of discovery, a small 
cadre of investigators is dependent upon an even smaller number of 
manufacturers for its tools of inquiry, and conflicts of interest com-
plicate research.” Although companies may sincerely take the interests 
of patients at heart they also have a – legitimate – interest in making a 
profit. These two interests do not always coincide and the commercial 
motive may hamper free and innovative research, especially when 
researchers also have conflicting roles (e.g., both company-advisor 
and principal investigator). Disclosure of potential conflict of interest 
is important, but insufficient, since it does not resolve the underlying 
conflict of interest itself. This issue has been underexposed in the 
ethical discussion up till now but warrants serious attention from 
researchers, companies, and regulators.
discussion
Deep brain stimulation is an established treatment in neurology 
and is emerging as experimental treatment in the field of psychiatry. 
Over the past years, bioethicists and philosophers have been work-
ing in close cooperation with clinicians and researchers to identify 
and discuss the most important ethical issues in both clinical prac-
tice and research. There is a growing corpus of literature available 
that addresses these issues. The most pressing issues to be explored 
in further bioethical research are the psycho-social and identity-
effects of DBS, its use in children, and the further development of 
responsible and transparent research practices.
Table 2 | Ethical guidelines for DBS research (based on: Nuttin et al., 
2002; Kuhn et al., 2009; Rabins et al., 2009; Clausen, 2010; Schlaepfer 
and Fins, 2010).
Ethical principles Requirements
Protection of research subject •  Performed by expert multidisciplinary 
teams
•  Strict inclusion criteria (including 
severity and refractoriness)
• Informed consent
• Long term follow up
• IRB oversight
•  Goal to improve patient’s life (no law 
enforcement, enhancement, or political 
purposes)
Autonomy of research 
subject
• Competence assessment
•  Informed consent; special attention to 
therapeutic misconception, hope, and 
despair
• No Financial barriers to withdraw
Quality of research • Only at expert centers
•  Independently reviewed protocols, 
hypothesis driven
• IRB oversight
•  Comprehensive outcome measures 
(including QoL, psycho-social impact)
• Long term follow up
Transparency •  Comprehensive registry (both trial and 
single-case)
•  Disclosure potential conflict of interest
Benefit to future patients •  Include all experimental treatment in trial
•  Comprehensive registry (both trial and 
single-case)
• Comparative studies
Special protection vulnerable 
groups
•  Inclusion limited to competent adult 
subjects
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